Port Washington, New York The Law Offices of Gary I. Fields PLLC ("LOGF") is pleased to announce the addition of Elliot Lee, Esq. in its Port Washington offices, expanding the firm's corporate, securities, finance and health care practices. "Elliot will enhance our ability to provide the highest quality corporate, finance and regulatory services to clients of all sizes on a very cost-effective basis," Gary Fields commented. "Elliot joins our team at a time of great change and consolidation in health care and other industries, and we are well positioned to help clients in these challenging times."
Elliot has concluded numerous prominent transactions in health care, biomedical and life sciences and has advised clients on FDA and other regulatory issues. In addition, he has significant experience in cosmetics (including devices), technology and the financial services industries. Elliot's experience extends to domestic and cross border transactions, both in the public and private markets.
Elliot has been a trusted advisor to numerous companies, bringing extensive experience in capital-raising transactions, including initial public offerings (IPOs), follow-on equity offerings, private placements, PIPES (private investment in public equities) and debt offerings. His clients include investment banks acting as underwriters and initial purchasers, as well as representing issuers. Elliot has significant experience in joint ventures, mergers and acquisitions, strategic alliances, tender offers, public-to-private transactions and other strategic transactions. He advises boards and management on corporate governance issues, state corporate law issues, SEC reporting and compliance issues, issues arising under the Sarbanes-Oxley Act, listed company obligations under stock exchange rules and an array of general corporate matters.
Before joining LOGF, Elliot was a member of the Corporate Department at Proskauer Rose LLP in New York City, the Healthcare and Life Sciences Corporate Finance Department at Dewey & LeBoeuf LLP in New York City, and he practiced in the Corporate Finance Department of Kim & Chang in Seoul, Korea, Korea's most prominent law firm.
Elliot received his J.D. from New York University School of Law and his B.A. from Northwestern University. He is admitted to practice law in New York and is a member of the New York State Bar Association.
Some representative transactions on which Elliot has worked include:
Represented UBS Investment Bank, as underwriter, in a $33 million follow-on equity offering of Indevus Pharmaceuticals, Inc., a U.S. biopharmaceutical company focusing on urological, gynecological and mens health conditions
Represented UBS Investment Bank, as underwriter, in a $35 million IPO of Omrix Biopharmaceuticals, Inc., an Israeli biosurgical and passive immunotherapy company
Represented UBS Investment Bank, as underwriter, in a $133 million follow-on equity offering of SFBC International, Inc., a U.S. global drug development services company
Represented Take-Two Interactive Software, Inc., a global publisher, developer and distributor of interactive entertainment software, hardware and accessories, in its successful defense of an attempted $2 billion hostile takeover bid by Electronic Arts Inc.
Represented UBS Investment Bank, as underwriter, in a $71 million follow-on equity offering of Geron Corporation, a U.S. biopharmaceutical company focusing on cancer and degenerative diseases
Represented UBS Investment Bank, as underwriter, in a $35 million follow-on equity offering of Neopharm, Inc., a U.S. biopharmaceutical company focusing on cancer
Represented UBS Investment Bank, as underwriter, in a $61 million follow-on equity offering in the U.S. and Canada of Neurochem Inc., a Canadian biopharmaceutical company focusing on neurological disorders
Represented Citigroup, as underwriter, in a $75 million IPO of Cynosure, Inc., a U.S. aesthetic laser treatment company
Represented MarketAxess Holdings Inc., a U.S. company that operates platforms for the electronic trading of corporate bonds and other fixed-income securities, in a $35 million PIPE transaction.
Represented First Albany Capital, as underwriter, in a $23 million follow-on equity offering of Impco Technologies, Inc., a U.S. alternative fuel technologies company
Represented UBS Investment Bank, as initial purchaser, in a $50 million convertible notes offering of Antigenics Inc., a U.S. biotechnology company focusing on cancer and infectious diseases
Represented an international investment bank and a U.S. hedge fund, in investigations by Korean regulatory authorities relating to alleged market manipulation
Represented a Korean bank, in a $180 million credit facility extended to a developing Eastern European country in connection with a project finance transaction
Represented an international private equity firm, in a $292 million acquisition of a Korean beverages company
Represented an international investment bank in the structuring of acquisitions of a Korean securities company, Korean credit card company, Korean asset management company and Korean insurance company
Represented HSBC in a $400 million floating rate notes cross-border securitization involving automobile loans originated in Korea
Represented an international investment bank in the structuring of a cross-border securitization involving assets originated in Korea